Pipeline

Our Programs

Scioto Biosciences’ leading clinical candidate SB-121 is poised to enter the clinic in 2019.

Our Focus

GI Immaturity in Premature Infants

Annually in the United States there are…

  • 60,000 infants with very low birth weight
  • 275,000 infants with low birth weight

Premature infants have greater nutritional needs in the neonatal period than at any other time of their lives.There is increasing understanding in the NICU of the importance of infant gut microbiome to overall health.

Focus

Immaturity of the preterm infant gut has devastating consequences, including:

  • Feeding intolerance
  • Late-onset sepsis
  • Necrotizing enterocolitis (NEC)
  • Long-term consequences such as development disabilities and adverse health outcomes

An FDA-approved, safe, efficacious, single-dose product for preterm infant GI health in the NICU is desperately needed. L. reuteri is widely recognized as an important bacteria in breastmilk. Scioto envisions SB-121 as a universal tool in the NICU for prevention of NEC, sepsis, death, and feeding intolerance in preterm infants.

Immaturity of the preterm infant gut has devastating consequences, including:

  • Feeding intolerance
  • Late-onset sepsis
  • Necrotizing enterocolitis (NEC)
  • Long-term consequences such as development disabilities and adverse health outcomes

An FDA-approved, safe, efficacious, single-dose product for preterm infant GI health in the NICU is desperately needed. L. reuteri is widely recognized as an important bacteria in breastmilk. Scioto envisions SB-121 as a universal tool in the NICU for prevention of NEC, sepsis, death, and feeding intolerance in preterm infants.